Alpha 2.0
Login Register
» Authors » Christopher Bates

Christopher Bates

Explore the profile of Christopher Bates including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 333
Followers 0
Related Specialties
General Medicine
Public Health
Toxicology
Top 10 Co-Authors
Ben Goldacre
Amir Mehrkar
John Parry
Brian Mackenna
Frank Hester
Jonathan Cockburn
Sam Harper
Alex J Walker
William J Hulme
Laurie A Tomlinson
Published In
BMJ Open
J Appl Toxicol
BMJ Med
Wellcome Open Res
J Surg Case Rep
Affiliations
Soon will be listed here.
Recent Articles
1.
Pathways to healthy ageing in Vanuatu: a qualitative evaluation of national policy priorities
Palagyi A, Gadsden T, Stephens J, Abel M, Peter L, Lee S, et al.
Lancet Reg Health West Pac . 2024 Sep; 51:101178. PMID: 39318548
Background: The Pacific Island country of Vanuatu is at the early stages of demographic ageing. The government is yet to develop a strategic approach to optimize the health and wellbeing...
2.
Changes in sick notes associated with COVID-19 from 2020 to 2022: a cohort study in 24 million primary care patients in OpenSAFELY-TPP
Schaffer A, Park R, Tazare J, Bhaskaran K, Mackenna B, Denaxas S, et al.
BMJ Open . 2024 Jul; 14(7):e080600. PMID: 38960458
Objectives: Long-term sickness absence from employment has negative consequences for the economy and can lead to widened health inequalities. Sick notes (also called 'fit notes') are issued by general practitioners...
3.
Predicting incident heart failure from population-based nationwide electronic health records: protocol for a model development and validation study
Nakao Y, Nadarajah R, Shuweihdi F, Nakao K, Fuat A, Moore J, et al.
BMJ Open . 2024 Jan; 14(1):e073455. PMID: 38253453
Introduction: Heart failure (HF) is increasingly common and associated with excess morbidity, mortality, and healthcare costs. Treatment of HF can alter the disease trajectory and reduce clinical events in HF....
4.
Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform
Zheng B, Tazare J, Nab L, Green A, Curtis H, Mahalingasivam V, et al.
Lancet Reg Health Eur . 2023 Nov; 34():100741. PMID: 37927438
Background: Timely evidence of the comparative effectiveness between COVID-19 therapies in real-world settings is needed to inform clinical care. This study aimed to compare the effectiveness of nirmatrelvir/ritonavir versus sotrovimab...
5.
Developmental and reproductive toxicity hazard characterization of 2-amino-2-methyl-1-propanol (AMP)
Garnick L, Bates C, Massarsky A, Spencer P, Sura P, Monnot A, et al.
J Appl Toxicol . 2023 Sep; 44(3):316-332. PMID: 37715655
2-Amino-2-methyl-1-propanol (AMP™) is a widely used pH stabilizer in personal care products (PCPs); thus, the safety implications of dermal AMP exposure remain of interest. We have previously reported that exposure...
6.
First dose COVID-19 vaccine coverage amongst adolescents and children in England: an analysis of 3.21 million patients' primary care records in situ using OpenSAFELY
Hopcroft L, Curtis H, Brown A, Hulme W, Andrews C, Morton C, et al.
Wellcome Open Res . 2023 Jun; 8:70. PMID: 37346822
The coronavirus disease 2019 (COVID-19) vaccination programme in England was extended to include all adolescents and children by April 2022. The aim of this paper is to describe trends and...
7.
Changes in medication safety indicators in England throughout the covid-19 pandemic using OpenSAFELY: population based, retrospective cohort study of 57 million patients using federated analytics
Fisher L, Hopcroft L, Rodgers S, Barrett J, Oliver K, Avery A, et al.
BMJ Med . 2023 Jun; 2(1):e000392. PMID: 37303488
Objective: To implement complex, PINCER (pharmacist led information technology intervention) prescribing indicators, on a national scale with general practice data to describe the impact of the covid-19 pandemic on safe...
8.
Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform
Nab L, Parker E, Andrews C, Hulme W, Fisher L, Morley J, et al.
Lancet Public Health . 2023 Apr; 8(5):e364-e377. PMID: 37120260
Background: COVID-19 has been shown to differently affect various demographic and clinical population subgroups. We aimed to describe trends in absolute and relative COVID-19-related mortality risks across clinical and demographic...
9.
Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY
Green A, Curtis H, Higgins R, Nab L, Mahalingasivam V, Smith R, et al.
BMJ Med . 2023 Mar; 2(1):e000276. PMID: 36936265
Objective: To ascertain patient eligibility status and describe coverage of antiviral drugs and neutralising monoclonal antibodies (nMAB) as treatment for covid-19 in community settings in England. Design: Retrospective, descriptive cohort...
10.
Protocol for an OpenSAFELY cohort study collecting patient-reported outcome measures using the TPP Airmid smartphone application and linked big data to quantify the health and economic costs of long COVID (OpenPROMPT)
Herrett E, Tomlin K, Lin L, Tomlinson L, Jit M, Briggs A, et al.
BMJ Open . 2023 Feb; 13(2):e071261. PMID: 36806073
Introduction: The impact of long COVID on health-related quality of-life (HRQoL) and productivity is not currently known. It is important to understand who is worst affected by long COVID and...